Alison Moliterno

Dr. Alison Moliterno

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
AMAlison Moliterno
Alison Moliterno
DWDonna M. Williams
Donna M. Williams
LGLaura I. Gutierrez-Alamillo
Laura I. Gutierrez-Alamillo
RSRoberto Salvatori
Roberto Salvatori
RIRoxann G. Ingersoll
Roxann G. Ingersoll
JSJerry L. Spivak
Jerry L. Spivak
The chronic myeloproliferative disorders (MPD) are clonal hematopoietic stem cell disorders of unknown etiology. We have reported defective thrombopoietin receptor (Mpl) protein expression in MPD patients. To determine whether the basis of abnormal Mpl protein expression was due to mutations in the Mpl gene, we sequenced Mpl cDNA from MPD patients. We found a single nucleotide substitution (G1238T) that results in a change from lysine to asparagine at amino acid 39 (K39N) in three African-American women referred for an evaluation of an MPD. We subsequently screened more than 400 patients and controls and found that the K39N substitution is a polymorphism restricted to African Americans and that ≈7% of African Americans are heterozygous for K39N. African Americans with the K39N polymorphism had a significantly higher platelet count than controls without the polymorphism ( P < 0.001) and reduced platelet protein Mpl expression. Expression of an Mpl cDNA containing the K39N substitution in cell lines was associated with incomplete processing and a reduction in Mpl protein, recapitulating the Mpl protein defect observed in platelets from individuals with K39N. K39N represents an identified functional Mpl polymorphism and is associated with altered protein expression of Mpl and a clinical phenotype of thrombocytosis.

20 August 2019 in Blood
Verified
Journal Article
Closed access
PDF file
HUHarshvardhan Upreti
Harshvardhan Upreti
JKJamil Kasmani
Jamil Kasmani
KDKathryn Dane
Kathryn Dane
EBEvan M. Braunstein
Evan M. Braunstein
MSMichael B. Streiff
Michael B. Streiff
SCShruti Chaturvedi
Shruti Chaturvedi
With timely and effective treatment, most patients with thrombotic thrombocytopenic purpura (TTP) survive their acute episode. In addition to the risk of relapse, TTP survivors have higher all-cause mortality than the general population and increased rates of chronic morbidities including hypertension, depression, and mild cognitive impairment. We conducted this retrospective-prospective cohort study to determine the incidence and prevalence of stroke after recovery from acute TTP and to test the hypothesis that lower ADAMTS13 activity after recovery from TTP is associated with an increased risk for stroke during remission. Of 170 consecutive patients treated for TTP at the Johns Hopkins Hospital between 1995 and 2018, 14 (8.2%) died during the index episode and 19 were followed for less than one month after recovery. Of the remaining 137 patients, 18 (13.1%) developed stroke unrelated to an acute TTP episode over a median observation period of 3.08 years, which is 5-fold higher than the expected prevalence of 2.6% from an age- and sex-matched reference population (P= 0.002). ADAMTS13 activity during remission was measured in 52 patients and was >70% in 44.2%, 40-70% in 23.1%, 10-39% in 25%, and 70%) and in 27.6% (8 of 29) patients with low ADAMTS13 activity ({less than or equal to} 70%) (P=0.007). In conclusion, stroke is common after recovery from TTP and is associated with reduced ADAMTS13 activity during remission. Key Points Stroke is more common in TTP survivors than in a age- and sex-matched reference US population. Lower ADAMTS13 activity during clinical remission after recovery from TTP is associated with stroke.

20 April 2023 in Blood
Verified
Journal Article
Open access
PDF file
AMAlison Moliterno
Alison Moliterno
HKHannah Kaizer
Hannah Kaizer
BRBRANDI REEVES
BRANDI REEVES
Polycythemia vera (PV) is a hematopoietic stem cell neoplasm defined by activating somatic mutations in the JAK2 gene and characterized clinically by overproduction of red blood cells, platelets, and neutrophils; a significant burden of disease-specific symptoms; high rates of vascular events; and evolution to a myelofibrosis phase or acute leukemia. The JAK2V617F variant allele frequency (VAF) is a key determinant of outcomes in PV, including thrombosis and myelofibrotic progression. Here, we critically review the dynamic role of JAK2V617F mutation burden in the pathogenesis and natural history of PV, the suitability of JAK2V617F VAF as a diagnostic and prognostic biomarker, and the utility of JAK2V617F VAF reduction in PV treatment.

1 December 2006 in Blood
Verified
Journal Article
Open access
PDF file
AMAlison Moliterno
Alison Moliterno
DWDonna M. Williams
Donna M. Williams
OROphelia Rogers
Ophelia Rogers
JSJerry L. Spivak
Jerry L. Spivak
An activating JAK2 mutation (JAK2 V617F) is present in the chronic myeloproliferative disorders (MPDs), polycythemia vera (PV), idiopathic myelofibrosis (IMF), and essential thrombocytosis (ET). JAK2 is also a chaperone for Mpl and responsible for its cell-surface expression. We observed a reciprocal relationship between neutrophil JAK2 V617F allele percentage and platelet Mpl expression in JAK2 V617F–positive PV, IMF, and ET patients. However, severely impaired platelet Mpl expression was present in JAK2 V617F–negative MPD patients. While JAK2 V617F allele status did not necessarily correlate with the clinical MPD phenotype, the degree of impaired platelet Mpl expression did. We conclude that multiple molecular abnormalities are involved in the pathogenesis of the MPDs and that aberrant Mpl expression may be a common denominator of aberrant signaling in both the JAK2 V617F–positive and JAK2 V617F–negative MPDs.

4 February 2010 in Haematologica
Verified
Journal Article
Closed access
PDF file
BSB. L. Stein
B. L. Stein
DWD. M. Williams
D. M. Williams
NWN.-Y. Wang
N.-Y. Wang
ORO. Rogers
O. Rogers
MIM. A. Isaacs
M. A. Isaacs
AMAlison Moliterno
Alison Moliterno
Background The JAK2V617F allele burden is a variable measure, determined by the frequency of mitotic recombination events and the expansion of JAK2V617F clones. Since variability in the JAK2V617F allele burden is partly responsible for the distinct phenotypes seen in the myeloproliferative disorders, the objective of this study was to identify modifiers of the allele burden. Design and Methods Blood samples were obtained between May 2005 and January 2009 from 272 patients with essential thrombocytosis, polycythemia vera, and myelofibrosis. The JAK2V617F allele burden was measured by an allele-specific quantitative polymerase chain reaction using DNA from purified neutrophils. Repeated measures, on average 2 years apart, were available for 104 patients. Results Sex, age at diagnosis, and disease duration all independently influenced the JAK2V617F allele burden. When considering all patients with myeloproliferative disorders, women had significantly lower allele burdens than men (P=0.04). In those patients with repeated measures, the increase in allele burden per year between the first and second evaluations was significantly less in females than in males. Among those who experienced disease evolution, females were 4.5 times more likely to have evolution from essential thrombocytosis to polycythemia vera, but 0.23 times as likely to have evolution from essential thrombocytosis to myelofibrosis. Conclusions Sex is an independent factor accounting for variability in the JAK2V617F allele burden. We speculate that lower allele burdens in females reflect a lower frequency of mitotic recombination events in females than in males, and should be considered when evaluating the relationship of allele burden to disease phenotype and also in evaluating responses to JAK2V617F-inhibitors. Because sex may influence genotype and/or clonal expansion, underpinning the variability in JAK2V617F allele burden, it will be important to explore factors that determine susceptibility to mitotic recombination events.

28 June 2011 in Haematologica
Verified
Journal Article
Closed access
BSB. L. Stein
B. L. Stein
DWD. M. Williams
D. M. Williams
COC. O'KEefe
C. O'KEefe
ORO. Rogers
O. Rogers
RIR. G. Ingersoll
R. G. Ingersoll
AMAlison Moliterno
Alison Moliterno
The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under question, and there has been interest in identifying additional mutations that may contribute to disease pathogenesis. Because ASXL1 lesions have been increasingly identified in myeloid neoplasms, we examined the relationships of ASXL1 mutation or deletion to both clinical phenotype and associated molecular features in 166 patients with myeloproliferative neoplasms. Exon 12 of ASXL1 was amplified from neutrophil genomic DNA and bidirectionally sequenced in 77 patients with myelofibrosis (including patients with primary and post-essential thrombocytosis or post-polycythemia myelofibrosis), 42 patients with polycythemia vera, 41 with essential thrombocytosis and 6 with post-myelofibrosis acute myeloid leukemia. Pyrosequencing assays were designed to determine the allele percentages of JAK2 V617F (G5073770T), ASXL1 2475dupA, and ASXL1 2846_2847del in neutrophil genomic DNA samples. Clinical and laboratory characteristics of patients with wild-type and ASXL1 mutations were then compared. We identified nonsense mutations or hemizygous deletion of ASXL1 in 36% of the patients with myelofibrosis, but very rarely among those with polycythemia vera or essential thrombocytosis. Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia. Myelofibrosis patients with ASXL1 lesions were more likely to have received anemia-directed therapy compared to those without lesions [15/26 (58%) versus 11/39 (23%); P=0.02]. Using serial banked samples and quantitative ASXL1 mutant allele burden assays, we observed the acquisition and accumulation of ASXL1 mutations over time in two patients with post-essential thrombocytosis myelofibrosis. ASXL1 haploinsufficiency is associated with a myelofibrosis phenotype in the context of other known and unknown lesions, and disruption of ASXL1 function may contribute to the disease pathogenesis of myelofibrosis.